Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Microbot Medical ( (MBOT) ) has shared an announcement.
Microbot Medical reported on May 5, 2026 that its LIBERTY Endovascular Robotic System is gaining traction among physicians and hospital executives following the full market release at the recent Society of Interventional Radiology annual meeting. The system has now been adopted by multiple accounts in key U.S. territories, including two sites that previously participated in the ACCESS-PVI pivotal clinical trial, underscoring commercial validation from early clinical users.
The company said growing interest is being helped by updated medical guidelines that encourage lower radiation exposure and better ergonomics to address staffing pressures in interventional care. Microbot plans to further elevate LIBERTY’s profile at the Global Embolization Symposium & Technologies conference in New York from May 14-17, 2026, while expanding its U.S. presence and building an international sales infrastructure led by its new EMEA sales vice president.
The most recent analyst rating on (MBOT) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is a single-use, remotely operated platform designed to improve precision, efficiency and safety in minimally invasive vascular interventions.
Average Trading Volume: 2,136,644
Technical Sentiment Signal: Sell
Current Market Cap: $141.7M
For an in-depth examination of MBOT stock, go to TipRanks’ Overview page.